Toronto General Hospital - UHN
Welcome,         Profile    Billing    Logout  
 11 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cherney, David
NCT04620590: An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function

Recruiting
4
17
Canada
Dapagliflozin 10 MG [Farxiga]
George Clinical Pty Ltd, University Medical Center Groningen, Ground Zero Pharmaceuticals
Diabetes Mellitus, Type 2, Impaired Renal Function
03/22
04/22
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
SUGARNSALT, NCT06217302: Sotagliflozin to Slow Kidney Function Decline in Persons with Type 1 Diabetes and Diabetic Kidney Disease

Recruiting
3
150
Canada, US
Sotagliflozin, INPEFA, Placebo
Alessandro Doria, Canadian Institutes of Health Research (CIHR), The Kidney Foundation of Canada, The Cleveland Clinic, University of Michigan, University of Colorado, Denver, Northwestern University, Washington University School of Medicine, State University of New York - Upstate Medical University, Providence Medical Research Center, Stanford University, Montefiore Medical Center, University of Toronto, University Health Network, Toronto, University of Calgary, University of Alberta, University of British Columbia, Institut de Recherches Cliniques de Montreal, LMC Diabetes & Endocrinology Ltd., Joslin Diabetes Center, Lexicon Pharmaceuticals, DexCom, Inc., University of Washington, Breakthrough T1D
Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
12/28
05/29
ASPIRE, NCT06072326: Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation

Not yet recruiting
2
36
Europe, Canada, US
Sotagliflozin, Ambrisentan, Ambrisentan and Sotagliflozin
University Medical Center Groningen, Juvenile Diabetes Research Foundation, Lexicon Pharmaceuticals
Type 1 Diabetes Mellitus With Diabetic Nephropathy
03/25
03/25
TREASURE-CKD, NCT05536804 / 2021-005273-47: A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
140
Europe, Canada, US, RoW
Tirzepatide, Placebo
Eli Lilly and Company, Eli Lilly and Company
Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
01/26
02/26
Overgaard, Chris
No trials found
Tavares, Suzana
No trials found

Download Options